Whole body HER2 quantification with 89Zr-Trastuzumab PET/CT to asses Zr-trastuzumab accumulation in HER2-mutated and HER2-overexpressing metastatic non-small cell lung cancer

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2026-525568-17-00

Enrollment

Registered

2026-07-30

Start date

Unknown

Completion date

Unknown

Last updated

2026-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HER2 mutation positive NSCLC

None listed

Sex/Gender

All

Age

18 Years to No maximum

None listed

Source: EU CTIS · Data processed: Jul 31, 2026